Investor Presentaiton

Performance: Full year 2022 sales £29.3bn, +13% Strong commercial execution across all product groups • ⚫ 10 products exceeded £1bn in sales 2021 sales 24,696 Specialty Medicines +15% CER • Specialty Medicines: strong demand for Benlysta, Nucala and new HIV products. Oncology +17% Vaccines +17% CER ⚫ Vaccines: Shingrix growth in all regions reflected post- pandemic rebound, new launches and strong commercial execution General Medicines: Strong Trelegy performance across all regions and antibiotic market recovery • Pandemic: Xevudy sales >£2bn Absolute values at AER; changes at CER, unless stated otherwise. GSK -1,082 -1,099 +13% CER General Medicines +1% CER 121 +19% AER Ex-pandemic +10% CER 26,998 Pandemic 914 2022 sales at 21 FX 27,912 Currency 1,412 2022 sales at 22 FX 29,324 Sales (£m) 16

View entire presentation